Pallas Capital Advisors LLC Has $806,000 Position in Illumina, Inc. (NASDAQ:ILMN)

Pallas Capital Advisors LLC lowered its holdings in Illumina, Inc. (NASDAQ:ILMN) by 5.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 6,029 shares of the life sciences company’s stock after selling 365 shares during the period. Pallas Capital Advisors LLC’s holdings in Illumina were worth $806,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ILMN. Green Alpha Advisors LLC raised its holdings in shares of Illumina by 82.9% in the 4th quarter. Green Alpha Advisors LLC now owns 4,693 shares of the life sciences company’s stock worth $627,000 after buying an additional 2,127 shares in the last quarter. ORG Wealth Partners LLC grew its position in Illumina by 68.1% in the fourth quarter. ORG Wealth Partners LLC now owns 3,030 shares of the life sciences company’s stock valued at $405,000 after acquiring an additional 1,227 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in Illumina by 2.2% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 18,170 shares of the life sciences company’s stock worth $2,369,000 after acquiring an additional 394 shares in the last quarter. Weybosset Research & Management LLC lifted its holdings in shares of Illumina by 14.3% during the fourth quarter. Weybosset Research & Management LLC now owns 20,638 shares of the life sciences company’s stock valued at $2,758,000 after acquiring an additional 2,586 shares during the period. Finally, Partnership Wealth Management LLC boosted its stake in shares of Illumina by 17.0% in the 4th quarter. Partnership Wealth Management LLC now owns 8,095 shares of the life sciences company’s stock valued at $1,082,000 after purchasing an additional 1,175 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of a number of recent analyst reports. Royal Bank of Canada increased their target price on shares of Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and cut their target price for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. TD Cowen increased their price target on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Piper Sandler cut their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Finally, Robert W. Baird increased their target price on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Trading Down 5.4 %

Shares of NASDAQ ILMN opened at $136.48 on Wednesday. The company’s 50 day simple moving average is $140.55 and its 200 day simple moving average is $133.10. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The firm has a market capitalization of $21.65 billion, a P/E ratio of -13.70 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the prior year, the business posted $0.33 EPS. The firm’s quarterly revenue was down 3.5% on a year-over-year basis. On average, analysts predict that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.